Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Catch up on the latest in GU cancers from leading experts at ASCO GU 2023. In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).
View all videos

GU Cancers 2023

ASCO Genitourinary Cancers Symposium 2023
16–18 February 2023 | San Francisco, CA
VJOncology avatar; VJ Oncology @VJOncology ·
May 18, 2024 1791839964499415220

🎥@elisabettasabet of @IEOufficiale discusses the Phase III PREcoopERA trial on giredestrant in premenopausal ER+/HER2- #breastcancer:

➡️https://ow.ly/rOye50RJWy9⬅️

@myESMO #ESMOBreast24

Reply on Twitter 1791839964499415220 Retweet on Twitter 1791839964499415220 0 Like on Twitter 1791839964499415220 2 Twitter 1791839964499415220
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791438701412663578

May is #SkinCancerAwarenessMonth 📣

According to The American Cancer Society an estimated 100,640 new #melanomas will be diagnosed in the USA in 2024 🇺🇸

Check out our skin cancer channel for the latest news and updates 👉 https://www.vjoncology.com/subject/skin-cancer

Image for the Tweet beginning: May is #SkinCancerAwarenessMonth 📣 According Twitter feed image.
Reply on Twitter 1791438701412663578 Retweet on Twitter 1791438701412663578 0 Like on Twitter 1791438701412663578 0 Twitter 1791438701412663578
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791410849124360509

📢We’re so excited! Only two weeks to go until #ASCO24!

From May 31st we’ll be interviewing #Oncology experts – to discover the latest in cancer treatment innovations head to ➡️http://VJOncology.com⬅️

@ASCO @VJOncology

Image for the Tweet beginning: 📢We’re so excited! Only two Twitter feed image.
Reply on Twitter 1791410849124360509 Retweet on Twitter 1791410849124360509 1 Like on Twitter 1791410849124360509 1 Twitter 1791410849124360509
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791396796133941327

#ESMOBreast24 | We had the pleasure to speak to @FioriPoulakaki, who discusses QoL issues after axillary treatment in #breastcancer.

Watch out for her interview and our latest podcast episode on our congress highlights at http://VJOncology.com🎙️

@myESMO #bcsm @Oncoalert

Image for the Tweet beginning: #ESMOBreast24 | We had the Twitter feed image.
Reply on Twitter 1791396796133941327 Retweet on Twitter 1791396796133941327 2 Like on Twitter 1791396796133941327 5 Twitter 1791396796133941327
Load More

GU Cancers 2023

ASCO Genitourinary Cancers Symposium 2023
16–18 February 2023 | San Francisco, CA
Catch up on the latest in GU cancers from leading experts at ASCO GU 2023. In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).
View all videos
VJOncology avatar; VJ Oncology @VJOncology ·
May 18, 2024 1791839964499415220

🎥@elisabettasabet of @IEOufficiale discusses the Phase III PREcoopERA trial on giredestrant in premenopausal ER+/HER2- #breastcancer:

➡️https://ow.ly/rOye50RJWy9⬅️

@myESMO #ESMOBreast24

Reply on Twitter 1791839964499415220 Retweet on Twitter 1791839964499415220 0 Like on Twitter 1791839964499415220 2 Twitter 1791839964499415220
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791438701412663578

May is #SkinCancerAwarenessMonth 📣

According to The American Cancer Society an estimated 100,640 new #melanomas will be diagnosed in the USA in 2024 🇺🇸

Check out our skin cancer channel for the latest news and updates 👉 https://www.vjoncology.com/subject/skin-cancer

Image for the Tweet beginning: May is #SkinCancerAwarenessMonth 📣 According Twitter feed image.
Reply on Twitter 1791438701412663578 Retweet on Twitter 1791438701412663578 0 Like on Twitter 1791438701412663578 0 Twitter 1791438701412663578
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791410849124360509

📢We’re so excited! Only two weeks to go until #ASCO24!

From May 31st we’ll be interviewing #Oncology experts – to discover the latest in cancer treatment innovations head to ➡️http://VJOncology.com⬅️

@ASCO @VJOncology

Image for the Tweet beginning: 📢We’re so excited! Only two Twitter feed image.
Reply on Twitter 1791410849124360509 Retweet on Twitter 1791410849124360509 1 Like on Twitter 1791410849124360509 1 Twitter 1791410849124360509
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791396796133941327

#ESMOBreast24 | We had the pleasure to speak to @FioriPoulakaki, who discusses QoL issues after axillary treatment in #breastcancer.

Watch out for her interview and our latest podcast episode on our congress highlights at http://VJOncology.com🎙️

@myESMO #bcsm @Oncoalert

Image for the Tweet beginning: #ESMOBreast24 | We had the Twitter feed image.
Reply on Twitter 1791396796133941327 Retweet on Twitter 1791396796133941327 2 Like on Twitter 1791396796133941327 5 Twitter 1791396796133941327
Load More

Watch all videos from ASCO GU 2023!

View all videos
1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
0:35
Primary analysis of TROPHY-U-01 Cohort 2
Daniel P. Petrylak • 16 Feb 2023
1:21
KEYNOTE-921: pembrolizumab plus docetaxel in chemotherapy-naïve mCRPC
Daniel P. Petrylak • 16 Feb 2023

Bladder Cancer at ASCO GU 2023!

View all
0:35
Primary analysis of TROPHY-U-01 Cohort 2
Daniel P. Petrylak • 16 Feb 2023
4:38
Impact of neoadjuvant chemo on pathological staging and survival in sarcomatoid bladder cancer
Arya Mariam Roy • 18 Feb 2023
1:45
Results from dataset analysis of CDH1-mutated urothelial carcinoma patients
Andrea Necchi • 18 Feb 2023
1:18
Updates from KEYNOTE-905: immunotherapy + cystectomy vs cystectomy alone in MIBC
Andrea Necchi • 18 Feb 2023

Prostate Cancer at ASCO GU 2023!

View all
1:21
KEYNOTE-921: pembrolizumab plus docetaxel in chemotherapy-naïve mCRPC
Daniel P. Petrylak • 16 Feb 2023
1:01
Updates from ECHOS: real world outcomes from mCSPC treatment with docetaxel
Orazio Caffo • 17 Feb 2023
0:55
Post-progression therapies in patients with mCRPC progressing after docetaxel
Orazio Caffo • 17 Feb 2023
1:10
Challenges facing new pathway inhibitor treatments in prostate cancer
Kamal Sahu • 16 Feb 2023

Kidney Cancer at ASCO GU 2023!

View all
1:27
Unmet needs regarding immunotherapy for renal cell carcinoma
Nazli Dizman • 24 Feb 2023
5:07
Association between time-of-day of ICI infusion and disease outcomes in metastatic RCC)
Nazli Dizman • 24 Feb 2023
2:04
Unmet educational needs in GU cancers
Thomas Powles • 16 Feb 2023
2:37
Key unmet needs in kidney cancer
Thomas Powles • 16 Feb 2023
The content of VJOncology is intended for healthcare professionals